IXENSOR
27.4.2022 08:02:08 CEST | Business Wire | Press release
iXensor Co., Ltd. (6734. TWO)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005097/en/
iXensor, the pioneer of mobile health, today announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business.
Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech® technology to digitize its new products through a separate technology licensing and joint development agreement, thereby providing Rohto Pharmaceutical's consumers with innovative self-testing portfolios including women's health and infectious diseases in Japan market.
iXensor's first product, PixoTest® Glucose Monitoring System, developed based on its PixoTech® platform, is the world's first US FDA-approved smartphone camera-based blood test dated in 2017. The PixoTech® , currently protected by more than 70 international patents, is iXensor's core technology platform that transforms smartphones into in vitro diagnostic instruments for biomedical analysis in point-of-care testing and self-testing. PixoTech® controls smartphones' camera sensing modules and screen lighting emissions with multiple wavelengths to analyze all types of immunoassay and enzymatic tests through the proprietary algorithm.
Mr. Hidetoshi Segi, Chief Strategy Officer of Rohto Pharmaceutical, commented, "By investing in iXensor, we can deepen our joint efforts on a series of new product developments, thus expanding our testing and diagnostic business through a wave of digital transformation. As the first step, we will receive a technical license for smartphone-based diagnostic devices and apps from iXensor to develop and sell innovative self-testing products."
Dr. Carson Chen, CEO of iXensor, expressed, "This partnership represents the unlimited potential and technical advantage of the PixoTech® platform to transform smartphones into precision medical diagnostic devices. The licensing business of PixoTech® technology started shifting in as the new engine to drive iXensor's growth."
In the post-pandemic era, iXensor endeavors to accelerate the growth of the at-home self-testing market and empower the evolution of the digital health ecosystem through licensing the PixoTech® technology. Thanks to that, PixoTech® can be flexibly applied to the digitalization of various lateral flow tests. In addition, it can shorten the lead time for IVD manufacturers venturing into the digital health business. It can also be applied to develop companion diagnostic or remote monitoring tools for pharmaceuticals to prove the efficacy of new classes of medications with actual test results collected from patients' smartphones with comfort at home.
About Rohto Pharmaceutical
Founded in 1899, Rohto Pharmaceutical is a renowned Japanese company that has successfully commercialized its research and development of consumer and pharmaceutical products worldwide. Rohto Pharmaceutical has established a robust product portfolio, including eye care, skincare, gastrointestinal medicines, and functional foods. Within the test drug business, the novel coronavirus antigen rapid test for medical institutions was launched in response to the global epidemic in addition to the existing pregnancy test, ovulation test, and flu rapid test products.
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest®
Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech®
platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, diabetes, and cardiovascular diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005097/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom